Alira Health says global biologics CDMO market reaches $23.2 billion in 2025
XBI•M&A activity and investment tilt toward US sites
M&A rose to 29 transactions in 2025; capability drove nearly 80% of deals.
The report also says 84% of USD 13.3 billion investment went to US sites.
Alira Health report sizes 2025 biologics CDMO market
Alira Health released its 2026 Biologics Contract Manufacturing Report, pegging the global biologics CDMO market at $23.2 billion in 2025.
Competitive advantage is shifting from scale to specialized manufacturing, regulatory execution and commercial track record as biologics complexity rises.
Top providers and scarce capacity support pricing power
The report says the top 10 CDMOs control 55% of market value, signaling sponsor preference for large, experienced global providers.
Scarce commercial-scale GLP-1 peptide and AAV gene therapy capacity supports pricing power, with sponsors paying up for supply security.
